BioLife Solutions Inc

BLFS remains in a Stage 2 advancing uptrend with bullish medium-term momentum, but recent rejection at the key resistance zone and overbought conditions have led to short-term exhaustion. Price is extended above rising EMAs and rejected at the highs. Execution is deferred until a pullback into the rising EMA support zone or prior breakout levels is absorbed, providing a higher-probability entry.

• ↑Q1 2026 revenue reached $27.5 M, up 25% YoY on strong biopreservation media demand
• ↑Adjusted EBITDA margin widened to 22%, reflecting scalable operational leverage
• ↓Top 20 customers generate 80% of BPM revenue, raising concentration risk